In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Obesity trial surge puts the focus back on decentralisation
Explore the evolving obesity clinical trials landscape and the role of decentralisation and new technologies in this recent CTA article.
-
The Pivotal Role of Patient Advocacy Organisations in Driving Rare Disease Therapeutic Development
ICON’s Dr Neena Nizar and Dr Jana Benesh discuss the ways effective engagement with PAOs is shaping rare disease research and contributing to better therapeutic outcomes. Read the article in IPI for insights into patient engagement in preclinical, clinical and post-approval phases of development.
-
Therapeutic Focus - Pushing Boundaries in Idiopathic Pulmonary Fibrosis Clinical Research
With more than 170 early stage IPF clinical programs, IPF is one of the most dynamic rare diseases spaces for development.
-
Blending Models for Better Sourcing Solutions
There is a growing trend among large and midsize pharma in turning toward more strategic partnerships to help them navigate the increasing complexity of the development landscape and the compounding macroeconomic constraints. Read our Whitepaper: Embracing a blended operating model for more details.
-
ICON’s advances on the perpetual path of innovation in laboratory solutions
Innovative laboratory solutions have the potential to optimise clinical research processes, create more efficient operations and improve sustainability to support wider organisational objectives. In this article published by R&D World, ICON outlines some of the new initiatives that are in progress to ensure the continued delivery of high quality results that meet sponsors’ needs – today and tomorrow.
-
Survey shows varied views on impact of new cancer drugs
This article published in The Pharma Letter highlights findings from an ICON survey has found that despite the increasing investment in emerging oncology-related therapeutics, developers have varied views on the impact of new cancer drugs for patients.
-
Innovation and flexibility in long-term follow-up studies
Read insights from Harpreet Gill VP, Real World Solutions, on how sponsors can optimise their LTFU studies to be flexible and cost-effective, with strategic planning and innovation, overcoming challenges while capturing valuable data insights.
-
Cover Story - Regulatory CMC: Enhancing Biologics Development
Preventing delays and accelerating the progression of these critical therapies.
-
The future of RWD and RWE in healthcare decision-making: Applications of novel real-world data collection methods for healthcare decision-making
Read insights from Jennifer Eriksson, Divisional Principal, on the use of real-world evidence and real-world data to inform healthcare decision-making and provide patients with rapid access to innovative healthcare technology.
-
Biomarker Identification a Challenge and Opportunity in Cancer Drug Development, Survey Finds
This news piece from Precision Medicine Online provides an overview of the findings from ICON’s recent survey of professionals engaged in oncology-related clinical research. It shares respondents' insights on how precision medicine approaches are changing development strategies and the to the extent these therapeutic advances will benefit patients in the future.
